Pivotal readout
CBT-001 eye drop meets both primary goals in phase 3 pterygium study
Grand Pharmaceutical Group and Cloudbreak Pharma reported that both doses of CBT-001, a reformulated nintedanib emulsion, beat placebo on eye redness after three months and on lesion length after a year (p<0.001) in a 659-patient international trial. Further analyses continue. If approved, it would be the first medicine for pterygium, which is now managed mainly with surgery.
- DrugCBT-001
- CompanyGrand Pharmaceutical Group
- CompanyCloudbreak Pharma
- TargetCarbonic anhydrase IX
- TrialNCT05456425
Written by Gosset from public sources. Source types: Press release · SEC/exchange filing. Sources are available to Gosset users. Log in to see them.